Infectious Disease Testing

Versiti provides several standard infectious disease screening tests, including:

• CMV Antibody
• Hepatitis B Surface Antigen
• Hepatitis C Core Antibody
• Hepatitis C Virus Antibody
• HIV Antibody
• Human T-Lymphotrophic Virus
• Trypanosoma cruzi Antibody (Chagas)
• West Nile Virus (WNV)

The Women’s Health Portfolio powered by Quantigen, part of Versiti Clinical Trials, utilizes the most advanced PCR technology. We provide accurate and clinically actionable information for the most common infections of the genital tract, and in less time than culture-based tests. The comprehensive panel includes 23 assays for bacterial, fungal, protozoan, mycoplasma and viral pathogens. A single vaginal swab can be tested using one or all assay panels, except HSV testing, which requires a separate swab from the base of an active lesion. Collection kits include clear instructions, sample collection materials, and secure, convenient transport containers.

The Uurinary Ttract Iinfection (UTI) test utilizes the most advanced qPCR technology to quantify infectious agents from patient urine. Intermediate and high positives are then tested for antibiotic sensitivity to help identify the most effective treatment. Our UTI panel includes individual tests for 16 bacterial and one fungal targets, all known to cause UTI. Follow-up antibiotic sensitivity testing phenotypically screens for susceptibility to a large array of common antibiotics used for both Gram-positive and Gram-negative bacteria. Clinicians can now prescribe the most appropriate antimicrobial treatment with no guesswork—and be alerted to possible antibiotic-resistance patterns in their geographic area. Test requires a single urine collection. Collection Kkits include clear instructions, sample collection materials, and secure, convenient transport containers.

In spring 2020, Quantigen, part of Versiti Clinical Trials, began patient testing for the novel coronavirus (SARS-CoV-2) in samples from state-sponsored collection sites located throughout Indiana. This endeavor was undertaken through a collaboration with both Eli Lilly and the Indiana State Department of Health (ISDH), with the latter providing testing instrumentation and reagents in support of Quantigen’s rapid mobilization. As of March o2021, Quantigen had tested in excess of 75,000 samples, with a plan to continue testing as needed for the foreseeable future.

In addition, Quantigen agreed in March 2021 to begin genetic variant surveillance using select CoV-positive samples taken from around the state. By performing whole-genome sequencing on these viral isolates and comparing them to a reference sequence, the ISDH can monitor the prevalence of variants with known clinical characteristics (e.g., the South African 501.V2). In addition, they can quickly detect and monitor other novel variants that might potentially (a) cause more severe illness, (b) spread more readily, and/or (c) evade immune surveillance as primed by current vaccines. All variant information from these screens will be shared with the CDC, which will then use the data to help inform its guidance on appropriate public safety measures.

CTA: Interested in discussing a project requiring infectious disease testing? Contact Us